Progress of targeted bone marrow hematopoietic microenvironment for acute myeloid leukemia
10.3760/cma.j.cn115356-20211205-00282
- VernacularTitle:靶向骨髓造血微环境治疗急性髓系白血病的研究进展
- Author:
Jinlian ZHAO
1
;
Yan MAN
;
Tonghua YANG
;
Yajie WANG
Author Information
1. 昆明理工大学医学院,昆明 650500
- Keywords:
Leukemia, myeloid, acute;
Tumor microenvironment;
Mesenchymal stem cells;
Exosomes;
Metabolism
- From:
Journal of Leukemia & Lymphoma
2022;31(12):762-765
- CountryChina
- Language:Chinese
-
Abstract:
Acute myeloid leukemia (AML) is a malignant clonal proliferative disease of immature myeloid cells in hematopoietic system. Although chemotherapy and hematopoietic stem cell transplantation could improve the survival of AML patients, their prognoses are still poor. Previous studies have shown that the abnormal regulation of bone marrow microenvironment (BMM) on leukemia stem cells is one of the important factors that make AML difficult to completely cure and easy to relapse. Studies on AML molecular biology and BMM are increasing. In-depth investigation on the changes of acute leukemia microenvironment and targeted intervention of abnormal BMM are expected to make new breakthroughs in the targeted therapy of AML and to improve the prognosis of patients. This review reviews the progress of BMM and targeted microenvironment therapy in AML.